Cargando…

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma

OBJECTIVE: This study aimed to identify the clinical significance of TP53 and common cytogenetic abnormalities. MATERIALS AND METHODS: A total of 114 patients with newly diagnosed multiple myeloma (MM) and TP53 abnormalities were selected from two large patient cohorts of collaborating hospitals fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Fang, Wang, Tongtong, Liu, Aijun, Li, Yanchen, Li, Ningning, Wang, Huan, Chen, Wenming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656118/ https://www.ncbi.nlm.nih.gov/pubmed/33938208 http://dx.doi.org/10.4274/tjh.galenos.2021.2021.0064

Ejemplares similares

Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2023)

Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
por: Geng, Chuanying, et al.
Publicado: (2022)

Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients
por: Hu, Ying, et al.
Publicado: (2019)

Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor
por: Wang, Ying, et al.
Publicado: (2022)

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
por: Jovanović, Katarina K., et al.
Publicado: (2019)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Retrospective analysis of 264 multiple myeloma patients
por: GENG, CHUANYING, et al.
Publicado: (2013)

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients
por: Yao, Weiqin, et al.
Publicado: (2023)

Development and validation of prognostic implications of chromosome abnormalities algorithm for newly diagnosed multiple myeloma
por: Luo, Tiancheng, et al.
Publicado: (2020)

Multiple myeloma with extramedullary plasmacytoma invading the skin and eyeballs following autologous stem cell transplantation: A case report
por: YANG, GUANGZHONG, et al.
Publicado: (2013)

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
por: Flynt, Erin, et al.
Publicado: (2020)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
por: Niparuck, Pimjai, et al.
Publicado: (2021)

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
por: Binder, M, et al.
Publicado: (2017)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma: A cohort study
por: Wang, Guorong, et al.
Publicado: (2017)

The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2021)

P22 THE PROGNOSTIC ROLE OF 1Q ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Attucci, I., et al.
Publicado: (2023)

Echocardiography‐defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients
por: Jian, Yuan, et al.
Publicado: (2022)

CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
por: Jian, Yuan, et al.
Publicado: (2022)

Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma
por: Feng, Xiangling, et al.
Publicado: (2022)

Prognostic Significance of Blood Transfusion in Newly Diagnosed Multiple Myeloma Patients without Autologous Hematopoietic Stem Cell Transplantation
por: Fan, Liping, et al.
Publicado: (2017)

Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion
por: Hao, Suyang, et al.
Publicado: (2017)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A real-world retrospective study
por: Li, Liping, et al.
Publicado: (2022)

The Association Between Low T3 Syndrome and Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study
por: Pan, Qingrong, et al.
Publicado: (2022)

The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients
por: You, Hongying, et al.
Publicado: (2022)

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53(abnormal) myeloma cells independently of the p53 pathway
por: Surget, Sylvanie, et al.
Publicado: (2014)

Significance of TP53 and immune-related genes to prostate cancer
por: Huang, Hang, et al.
Publicado: (2021)

Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
por: Martello, M., et al.
Publicado: (2022)

Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma
por: Dosani, T, et al.
Publicado: (2017)

Concurrent Polycythemia Vera with Newly Diagnosed Multiple Myeloma: Case Report and Literature Review
por: Yuan, Jing, et al.
Publicado: (2023)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
por: Hsu, Pei, et al.
Publicado: (2015)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_71qqn2igd0hhsdb8j7lvki8u6u